Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV

Biotechnology
WebsiteInvestor RelationsSEC
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

$1.7B

Market Cap • 9/11/2026

1999

(27 years)

Founded

2008

(18 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Belgium

Belgium

Country

Valuation

P/B

0,5

P/S

1,5

P/EBITDA

3,4

P/OCF

—

P/FCF

—

P/E

2,5

BVPS

56,5

EPS

10,6

Market Cap

Market Cap

1,7B

EV

-814,1M

EV/Revenue

-0,7

EV/EBITDA

-1,6

EV/EBIT

-1,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

257,7M

Profitability

Gross Margin

97,5%

EBITDA Margin

43,3%

EBIT Margin

41,1%

Net Margin

60%

D&A/EBITDA

0%

R&D/Revenue

23,7%

Capex/Revenue

0,5%

Capex/D&A

20,6%

Capex/OCF

-2%

SBC/OCF

—

% PPE

2,3%

% Goodwill

0%

ROE

20,4%

ROIC

38,9%

Growth

CAGR Revenue 5Y

10,1%

CAGR OCF 5Y

-13%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

32,8

Quick Ratio

32,6

Interest Coverage

21497,6%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium